epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-512, Phase III. Recruitment complete

Moderate to severe ulcerative colitis

WGB-512 induction against placebo in moderate to severe ulcerative colitis. Sponsor: Woodgrove Biologics (fictional), Immunology and GI.

QTLs at a glance

Data to September 30th 2026. Each measure links to its chart below.

Stopped study treatment early

9.1% against 15%

On course Within range

Ineligible patients randomised

2.1% against 5%

On course Within range

Missing primary endpoint data

7.8% against 15%

On course Within range

Lost to follow-up or withdrew consent

3.2% against 6%

On course Within range

Will the result hold?

Quality tolerance limits (acceptable ranges, in ICH E6(R3)), most important first. Priority is how likely this study's design makes a breach, times how strongly the evidence links the measure to a reliable result. Each has an early-warning line, a limit and a critical line where the study's power would fall to the escalation level.

RankQTLLikelihoodImpactWhy it is likely hereWatched at sites byWarningLimitCritical
1Stopped study treatment earlyEvidence grade B32
  • Placebo or no-added-treatment control arm (PD-05)From the design: What does the control arm receive? Placebo or no added treatment
12.5%15%22%
2Ineligible patients randomisedEvidence grade B22
  • Comorbidity exclusions (PD-15)From the design: Does the protocol exclude common comorbidities? Yes
  • Restrictive eligibility criteria and protocol complexity (EB-04)From the design: How many non-essential exclusions does the protocol carry? One or two
  • Eligibility criteria exclude patients (comorbidity, age, performance status, language) (PB-02)From the design: How many non-essential exclusions does the protocol carry? One or two; Does the protocol exclude common comorbidities? Yes
  • Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) (PD-01)From the design: How many non-essential exclusions does the protocol carry? One or two
  • Number of eligibility criteria and complexity growth (PD-02)From the design: How many non-essential exclusions does the protocol carry? One or two
4%5%14.5%
3Missing primary endpoint dataEvidence grade A13None of its drivers applies to this design10.1%15%33.2%
4Lost to follow-up or withdrew consentEvidence grade A13None of its drivers applies to this design4.5%6%24.3%

Stopped study treatment early

Within range% of patients; benchmark median 10.7%

Show data
Stopped study treatment early: running rate by month
MonthPatientsRate
Mar 202210%
Jun 2022110%
Sep 2022290%
Dec 2022512%
Mar 2023792.5%
Jun 20231162.6%
Sep 20231405%
Dec 20231677.2%
Mar 20241927.8%
Jun 20242196.8%
Sep 20242616.1%
Dec 20242926.8%
Mar 20253168.5%
Jun 20253518.5%
Sep 20253808.4%
Dec 20254159.2%
Mar 20264488.7%
Jun 20264719.1%

epiClinical assumption: above the Phase III benchmark of 11.5%; a breach dilutes the treatment effect and reduces power

Ineligible patients randomised

Within range% of patients; benchmark median 3.2%

Show data
Ineligible patients randomised: running rate by month
MonthPatientsRate
Mar 202210%
Jun 2022110%
Sep 2022290%
Dec 2022510%
Mar 2023792.5%
Jun 20231162.6%
Sep 20231402.1%
Dec 20231672.4%
Mar 20241922.1%
Jun 20242191.8%
Sep 20242611.5%
Dec 20242922.1%
Mar 20253162.2%
Jun 20253512.3%
Sep 20253802.1%
Dec 20254151.9%
Mar 20264482%
Jun 20264712.1%

epiClinical assumption: above the 3.2% median; eligibility errors were reported in 39% of 82 trials

Missing primary endpoint data

Within range% of patients; benchmark median 7.9%

Show data
Missing primary endpoint data: running rate by month
MonthPatientsRate
Sep 202210%
Dec 2022110%
Mar 2023290%
Jun 2023513.9%
Sep 2023797.6%
Dec 202311412.3%
Mar 202413810.1%
Jun 20241659.1%
Sep 20241908.4%
Dec 20242178.8%
Mar 20252598.9%
Jun 20252898.7%
Sep 20253138.3%
Dec 20253487.8%
Mar 20263777.4%
Jun 20264127.8%

The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it

Lost to follow-up or withdrew consent

Within range% of patients; benchmark median 3.7%

Show data
Lost to follow-up or withdrew consent: running rate by month
MonthPatientsRate
Mar 202210%
Jun 2022110%
Sep 2022290%
Dec 2022510%
Mar 2023790%
Jun 20231160.9%
Sep 20231401.4%
Dec 20231671.8%
Mar 20241921.6%
Jun 20242191.8%
Sep 20242611.9%
Dec 20242922.1%
Mar 20253162.2%
Jun 20253512%
Sep 20253802.6%
Dec 20254152.7%
Mar 20264482.9%
Jun 20264713.2%

epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status

Patients needed before a QTL is judged: 50. epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01).

Breaches and decisions

Near miss

Missing primary endpoint data

Early warning October 2023
Status
Watched; closed without action
What the evaluation found
A run of missed six-month visits at two sites, during a change of study nurse, pushed missing endpoint data over the early-warning line. Both sites rebooked the visits they could, and the rate fell back below the line within six months.
Why it matters
None lasting: the rate stayed well inside the acceptable range.

A fictional scenario written to show a warning that needed watching but not action.

Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.